| Biomarker ID | 427 |
| PMID | 19239456 |
| Year | 2009 |
| Biomarker | p53 |
| Biomarker Basis | Expression Based |
| Biomolecule | Protein |
| Source | Tissue |
| Subjects | Humans |
| Regulation | Increased Expression with Overall Death |
| Odds Ratio/Hazard Ratio/Relative Risk | Univariate: HR: 2.37 (95% CI 1.84–3.05); Multivariate: HR: 1.57 (95% CI 1.21-2.05) |
| Effect on Pathways | Pathways Include:- Apoptosis intrinsic pathway, Thyroid cancer,BARD1 signaling events,Fluoropyrimidine activity,Tumor suppressor Arf inhibits ribosomal biogenesis |
| Experiment | Overall Survival Vs No Survival |
| Type of Biomarker | Prognostic |
| Cohort | The analysis included 1844 cancerous cores from 705 eligible patients with clinically localized prostate cancer, who were treated conservatively. |
| Senstivity | NA |
| Specificity | NA |
| AUC | NA |
| Accuracy | NA |
| Level Of Significance | Univariate: p<0.001; Multivariate: p=0.001; |
| Method Used | immunohistochemistry |
| Clinical | No |
| Remarks | NA |
| Clinical Trial Number | NA |
| Degree Of Validity | Not validated on independent patient dataset |
| Technical Name | TP53 |